Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

Not Applicable

Completed

• Conditions: Liver Carcinoma
• Interventions: Radiation: 18F-RD2

• Registration Number: NCT05681234
• Lead Sponsor: Affiliated Hospital of Jiangnan University

Brief Summary

This is a single arm study to evaluate the safety and biodistribution of 18F-labeled RD2 PET/CT Imaging in patients with small liver carcinoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-08-24
• Primary Completion: 2022-11-02
• Status Verified: 2022-12
• Study Completion: 2022-12-20
• Study First Submitted: 2022-12-27
• Study First Submitted QC: 2022-12-27
• Last Update Submitted: 2022-12-27
• Study First Posted: 2023-01-12
• Last Update Posted: 2023-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Patients with highly suspected tumor；
2. Patients underwent PET/CT examination within 1 week;
3. Patients voluntarily signed informed consent;
4. Over 18 years old, male or female.

Exclusion Criteria

1. Pregnant women;
2. Lactating women;
3. Patients with impaired renal function.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
18F-RD2	18F-RD2	-

Primary Outcome Measures

Name	Time	Method
Evaluation of tissue distribution of 18F-RD2	2 hours	Biodistribution of 18F-RD2 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 18F-RD2 scans will be reported.

Trial Locations

Locations (1)

Affiliated Hospital of Jiangnan University; 🇨🇳 Wuxi, Jiangsu, China